Literature DB >> 26476574

Increased radiosensitivity of HPV-positive head and neck cancers: Molecular basis and therapeutic perspectives.

Haïtham Mirghani1, Furrat Amen2, Yungan Tao3, Eric Deutsch4, Antonin Levy4.   

Abstract

Human papillomavirus driven head and neck squamous cell carcinoma (HNSCC), particularly oropharyngeal squamous cell carcinoma (OPSCC), are characterized by a significant survival advantage over their HPV-negative counterparts. Although the reasons behind this are still not fully elucidated, it is widely accepted that these tumors have a higher response to ionizing radiation that might explain their favorable outcomes. Potential underlying intrinsic mechanisms include impaired DNA repair abilities, differences in activated repopulation-signaling pathways and cell cycle control mechanisms. The role of the microenvironment is increasingly highlighted, particularly tumor oxygenation and the immune response. Recent studies have shown a distinct pattern of intratumoral immune cell infiltrates, according to HPV status, and have suggested that an increased cytotoxic T-cell based antitumor immune response is involved in improved prognosis of patients with HPV-positive OPSCC. These significant milestones, in the understanding of HPV-induced HNSCC, pave the way to new therapeutic opportunities. This article reviews the current evidence on the biological basis of increased radiosensitivity in HPV-positive HNSCC and discusses potential therapeutic implications.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Head and neck cancer; Human papillomavirus 16; Oropharyngeal; Oropharynx; Radiation; Treatment

Mesh:

Year:  2015        PMID: 26476574     DOI: 10.1016/j.ctrv.2015.10.001

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  44 in total

1.  Roles of Ki-67 and p16 as biomarkers for unknown primary head and neck squamous cell carcinoma.

Authors:  Toshiya Maebayashi; Naoya Ishibashi; Takuya Aizawa; Masakuni Sakaguchi; Tsutomu Saito; Jiro Kawamori; Yoshiaki Tanaka; Yukari Hirotani; Taku Homma
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-02-12       Impact factor: 2.503

Review 2.  HPV, hypoxia and radiation response in head and neck cancer.

Authors:  Eva-Leonne Göttgens; Christian Ostheimer; Paul N Span; Jan Bussink; Ester M Hammond
Journal:  Br J Radiol       Date:  2018-03-14       Impact factor: 3.039

Review 3.  What you need to know: updates in penile cancer staging.

Authors:  Mahmoud I Khalil; Mohamed H Kamel; Jasreman Dhillon; Viraj Master; Rodney Davis; Ali J Hajiran; Philippe E Spiess
Journal:  World J Urol       Date:  2020-06-22       Impact factor: 4.226

4.  Is there a patient population with squamous cell carcinoma of the head and neck region who might benefit from de-intensification of postoperative radiotherapy? : A monocentric retrospective analysis of a previously defined low-risk patient population treated with standard-of-care radiotherapy.

Authors:  Yonca Onbasi; Sebastian Lettmaier; Markus Hecht; Sabine Semrau; Heinrich Iro; Marco Kesting; Rainer Fietkau; Marlen Haderlein
Journal:  Strahlenther Onkol       Date:  2019-01-04       Impact factor: 3.621

5.  Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy.

Authors:  Dan Ou; Julien Adam; Ingrid Garberis; Pierre Blanchard; France Nguyen; Antonin Levy; Odile Casiraghi; Philippe Gorphe; Ingrid Breuskin; François Janot; Stephane Temam; Jean-Yves Scoazec; Eric Deutsch; Yungan Tao
Journal:  Oncoimmunology       Date:  2017-07-05       Impact factor: 8.110

Review 6.  Pharmacologic inhibition of ataxia telangiectasia and Rad3-related (ATR) in the treatment of head and neck squamous cell carcinoma.

Authors:  Pooja Karukonda; Diana Odhiambo; Yvonne M Mowery
Journal:  Mol Carcinog       Date:  2021-12-29       Impact factor: 4.784

7.  FDG-PET/CT for treatment response assessment in head and neck squamous cell carcinoma: a systematic review and meta-analysis of diagnostic performance.

Authors:  Nils Helsen; Tim Van den Wyngaert; Laurens Carp; Sigrid Stroobants
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-24       Impact factor: 9.236

8.  Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16+ cancer.

Authors:  Ugur Sahin; Fulvia Vascotto; Nadja Salomon; Abderaouf Selmi; Christian Grunwitz; Anthony Kong; Eliana Stanganello; Jennifer Neumaier; Jutta Petschenka; Mustafa Diken; Sebastian Kreiter; Özlem Türeci
Journal:  Cancer Immunol Immunother       Date:  2021-12-31       Impact factor: 6.630

9.  Loss of TGFβ signaling increases alternative end-joining DNA repair that sensitizes to genotoxic therapies across cancer types.

Authors:  Qi Liu; Luis Palomero; Jade Moore; Ines Guix; Roderic Espín; Alvaro Aytés; Jian-Hua Mao; Amanda G Paulovich; Jeffrey R Whiteaker; Richard G Ivey; George Iliakis; Daxian Luo; Anthony J Chalmers; John Murnane; Miquel Angel Pujana; Mary Helen Barcellos-Hoff
Journal:  Sci Transl Med       Date:  2021-02-10       Impact factor: 17.956

10.  [18F]PARPi Imaging Is Not Affected by HPV Status In Vitro.

Authors:  Navjot Guru; Paula Demétrio De Souza França; Giacomo Pirovano; Cien Huang; Snehal G Patel; Thomas Reiner
Journal:  Mol Imaging       Date:  2021-01-20       Impact factor: 4.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.